clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells. Adaptive Biotechnologies received its third approval from the FDA for the use of its next-generation ...
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk This multicenter, single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results